Dolasetron Tablets Suppliers & Bulk Manufacturers
Available Forms: Tablets
Available Strengths: 50 mg
Reference Brands: Anzemet(US & EU)
Category:
Antiemetic
Dolasetron is a 5-HT3 receptor antagonist that blocks serotonin in the gastrointestinal tract and brain, reducing nausea and vomiting. It effectively prevents chemo- and post-operative nausea, supporting symptom relief, enhanced comfort, and improved quality of life for patients undergoing cancer treatment or surgery.
Dolasetron tablets is available in Tablets
and strengths such as 50 mg.
Sourced from GMP-certified and ISO-compliant manufacturers, this API meets
global pharmacopeia standards (USP/EP/JP as applicable). Ideal for pharmaceutical
formulation and commercial manufacturing, Dolasetron tablets is supplied in
bulk quantities with complete regulatory support including DMF, COA, and MSDS.
|
Technical Specifications & Supply Details
|
| Lead Time |
7 to 60 days (depending on batch size & schedule) |
| MOQ |
As per manufacturer’s batch size |
| COA |
Available with every batch |
| Regulatory Dossier / DMF |
Available upon request |
| Export Documentation |
FSC, COA, Manufacturing License, Product Permission |
| Standards |
IP, BP, USP |
| Certifications |
WHO-GMP, EU-GMP, USFDA (as applicable) |
Dolasetron tablets can be exported to over 30 countries across Asia, Africa, Europe,
and Latin America. Flexible packaging, competitive pricing, and a verified supplier
network make Pharmatradz a trusted sourcing partner for pharmaceutical companies
and contract manufacturers worldwide.
Product Description:
Dolasetron tablets, marketed as Anzemet, are approved in the US by the FDA and in the EU via EMA for preventing nausea and vomiting associated with chemotherapy and surgery. Regulatory approval requires comprehensive dossiers including clinical efficacy, safety data, manufacturing standards, and pharmacovigilance plans. The FDA reviews detailed clinical trial and quality data for timely approval, while the EMA ensures compliance with regional safety and quality standards. For guidance on dossier preparation, regulatory pathways, and market access, visit PharmaTradz. Proper regional adherence supports swift approval, safe usage, and worldwide availability, helping patients manage chemotherapy-related nausea and enhance treatment compliance globally.
Disclaimer: By continuing to browse, you agree to the terms of use of this website and the Trade Marks displayed, in compliance with the provisions of the Trademark Act, 1999, Section 30 and 30(1) under 'Fair use.'
The Trade Mark owner has been correctly identified under the heading Manufacturer / TM Owner as required by the Act.
Back to Listing